Chronic Hepatitis Delta Virus (HDV) Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Hepatitis delta, the most severe form of viral hepatitis in humans, is caused by infection with the hepatitis delta virus (HDV), which stands alone in the genus Deltaviridae. This unique virus relies on the presence of the hepatitis B virus (HBV) for replication, forming a symbiotic relationship. HDV infection produces two forms of an RNA-binding protein, known as the long and small delta antigens (Ag), with the host cell providing essential proteins for replication, notably RNA-directed RNA polymerase activity. Consequently, HDV can only cause disease in individuals who are already infected with HBV. Transmission of HDV primarily occurs through the parenteral route, typically via exposure to contaminated blood or blood products. The hepatitis delta virus expresses a single protein, the hepatitis delta antigen (HDAg), which forms a nucleocapsid-like structure with the viral genome. There are two forms of HDAg: small and large. These antigens and the single-stranded RNA genome are enveloped in a lipid membrane embedded with surface antigen proteins derived from HBV (HBsAg).
• HDV is distributed worldwide, with its prevalence locally dependent on the prevalence of HBV. It’s estimated that approximately 5% of individuals carrying HBsAg worldwide are co-infected with HDV. The incidence of HDV-related disease tends to increase with age, peaking between 50 and 59 years, then declining slightly by age 70.

Thelansis’s “Chronic Hepatitis Delta Virus (HDV) Infection Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hepatitis Delta Virus (HDV) Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chronic Hepatitis Delta Virus (HDV) Infection across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chronic Hepatitis Delta Virus (HDV) Infection Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Chronic Hepatitis Delta Virus (HDV) Infection – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Chronic Hepatitis Delta Virus (HDV) Infection, Chronic Hepatitis Delta Virus (HDV) Infection market outlook, Chronic Hepatitis Delta Virus (HDV) Infection competitive landscape, Chronic Hepatitis Delta Virus (HDV) Infection market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)